产品
编 号：F153681
分子式：C21H24ClNO4S
分子量：421.94
分子式：C21H24ClNO4S
分子量：421.94
产品类型
规格
价格
是否有货
结构图
CAS No: 141335-10-6
产品详情
生物活性：
LCB-2853 is an antagonist of thromboxane A2 (TXA2) receptor, with antiplatelet and antithrombotic activities.
体内研究：
In dog coronary stenosis, LCB 2853 shows a very high efficacy with ED50 of 7.2 μg/kg. In rat venous thrombosis induced by combination of venous injury and blood stasis, perfused LCB 2853 decreases the weight of thrombi in a dose related manner with ED50 of 220 μg/kg/min. In vivo, both against platelet aggregation and vasoconstriction, LCB 2853 shows an ED50 lower than 1 mg/kg i.v. in rat AA-induced thrombocytopenia or U 46619-induced hypertension (ED50 = 0.25 and 0.16 mg/kg) as well as in AA-induced sudden death in the mouse (ED50 = 0.44 mg/kg). The U 46619-induced bronchoconstriction is blocked after i.v. administration of LCB 2853 (ED50 = 18.4 μg/kg).
LCB-2853 is an antagonist of thromboxane A2 (TXA2) receptor, with antiplatelet and antithrombotic activities.
体内研究：
In dog coronary stenosis, LCB 2853 shows a very high efficacy with ED50 of 7.2 μg/kg. In rat venous thrombosis induced by combination of venous injury and blood stasis, perfused LCB 2853 decreases the weight of thrombi in a dose related manner with ED50 of 220 μg/kg/min. In vivo, both against platelet aggregation and vasoconstriction, LCB 2853 shows an ED50 lower than 1 mg/kg i.v. in rat AA-induced thrombocytopenia or U 46619-induced hypertension (ED50 = 0.25 and 0.16 mg/kg) as well as in AA-induced sudden death in the mouse (ED50 = 0.44 mg/kg). The U 46619-induced bronchoconstriction is blocked after i.v. administration of LCB 2853 (ED50 = 18.4 μg/kg).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备